The Effects of Rosiglitazone, Metformin, and Estradiol-Cyproterone Acetate on Lean Patients With Polycystic Ovary Syndrome

Basit Öğe Kaydı
dc.contributor.authorCetinkalp, Sevki
dc.contributor.authorKaradeniz, Muammer
dc.contributor.authorErdogan, Mehmet
dc.contributor.authorOzgen, Gokhan
dc.contributor.authorSaygili, Fuesun
dc.contributor.authorYilmaz, Candeger
dc.date.accessioned2019-10-27T20:52:04Z
dc.date.available2019-10-27T20:52:04Z
dc.date.issued2009
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Polycystic ovary syndrome (PCOS) is characterized by anovulation, infertility, and hyperandrogenism. The present study aims to compare the clinical, biochemical, and hormonal changes in PCOS patients taking estradiol-cyproterone acetate (ECA), metformin (MET), and rosiglitazone (ROSI). Methods: Ninety-four patients with PCOS were randomized according to the therapy they received as follows: MET 2 g/d group (n = 47), ROSI 4 mg/d group (n = 14). and 35 mu g ethinyl estradiol-2 mg cyproterone acetate group (ECA) (n = 33). Complete hormonal assays, lipid profile, glucose, and insulin levels were studied over a 4-months period. Results: Patients randomized to the MET group lost more weight and had a greater reduction in BMI compared with baseline (P = 0.006 and P = 0.004). The reduction in triglyceride levels and high-sensitivity C-reactive protein (hs-CRP) were statistically significant in the MET group while no changes were observed in the other groups. Regarding HDL levels, did not change in MET and ECA groups, but there was a significant increase compared with baseline in the ROSI group (P = 0.04). Mann-Whitney U test showed that the change (a tendency of reduction) was more significant in PCOS patients on MET for both total cholesterol and LDL-cholesterol (P < 0.001). The rate of improvement in oligomenorrhea was similar in all 3 treatments (P = 0.202). Conclusion: Our data show that in women with PCOS, ECA is more effective than insulin-sensitizing drugs such as rosiglitazone and metformin in improving menstrual pattern and reducing serum free-testosterone levels. MET, an insulin-sensitizing drug, is more effective in reducing fasting insulin levels than the ECA.en_US
dc.identifier.doi10.1097/TEN.0b013e3181a58772
dc.identifier.endpage97en_US
dc.identifier.issn1051-2144
dc.identifier.issn1539-9192
dc.identifier.issn1051-2144en_US
dc.identifier.issn1539-9192en_US
dc.identifier.issue3en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage94en_US
dc.identifier.urihttps://doi.org/10.1097/TEN.0b013e3181a58772
dc.identifier.urihttps://hdl.handle.net/11454/43186
dc.identifier.volume19en_US
dc.identifier.wosWOS:000266186500002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofEndocrinologisten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectpolycystic ovary syndromeen_US
dc.subjectdyslipidemiaen_US
dc.subjectrosiglitazoneen_US
dc.subjectmetforminen_US
dc.subjectestradiol-cyproterone acetateen_US
dc.titleThe Effects of Rosiglitazone, Metformin, and Estradiol-Cyproterone Acetate on Lean Patients With Polycystic Ovary Syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu